Nature Reviews Drug Discovery
Springer Science and Business Media LLC
ISSN: 1474-1776 E-ISSN: 1474-1784 Q1
United Kingdom
English
Medicine
SJR: 32.577
H-Index: 428
Journal Metrics
Articles
384
Authors
654
Citations
0
H-Index
0
About this Journal
Nature Reviews Drug Discovery is a monthly journal aimed at everyone working in the drug discovery and development arena. In addition to the highest-quality reviews and perspectives covering a broad scope, each issue includes news stories that investigate the hottest topics in drug discovery, timely summaries of key primary research papers, and concise updates on the latest advances in areas such as new drug approvals, patent law and emerging industry trends and strategies.
384
Articles
654
Authors
2
Volumes
19
Issues
2024–2026
Year Range
Journal Analytics
Publication Trend
Articles per Volume
Author Growth
Monthly Publications (Last 12 Months)
Top Contributing Authors
1
Sarah Crunkhorn
95 articles
2
Asher Mullard
89 articles
3
Katie Kingwell
21 articles
4
M. Teresa Villanueva
19 articles
5
Alex Eccleston
18 articles
6
Paul Verdin
8 articles
7
Tudor I. Oprea
3 articles
8
Xiaoyuan Chen
3 articles
9
Kaniaw Dilzer
3 articles
10
Rachel M. Webster
3 articles
Latest Articles
Can multispecific biologics break the efficacy ceiling?
Asher Mullard
Jul 01, 2026 10.1038/d41573-026-00106-5
Novel drug targets in 2025
Sorin Avram, Liliana Halip, Ramona Curpan et al.
Jul 01, 2026 10.1038/d41573-026-00102-9
The unglamourous AI wins that are quietly transforming drug discovery and development
Asher Mullard
Jul 01, 2026 10.1038/d41573-026-00099-1
Upcoming FDA approval decisions in Q3 2026
Swetha Kota
Jul 01, 2026 10.1038/d41573-026-00103-8
Antiviral peptide nabs FDA approval for hepatitis delta virus infection
Asher Mullard
Jul 01, 2026 10.1038/d41573-026-00101-w
First CD123-targeted ADC secures FDA approval for rare blood cancer
Asher Mullard
Jul 01, 2026 10.1038/d41573-026-00100-x
Advancing ferroptosis-targeted therapies
M. Teresa Villanueva
Jul 01, 2026 10.1038/d41573-026-00098-2
Analysis of a decade of post-authorisation studies for medicines approved by the EMA
Caroline Voltz-Girolt, Guillem Wetherell Mateu, Carla Torre et al.
Jul 01, 2026 10.1038/d41573-026-00082-w
Implantable hydrogel encapsulates ‘living therapeutics’
Katie Kingwell
Jul 01, 2026 10.1038/d41573-026-00096-4
Reply to ‘Stimulating medicines repurposing in the EU: a pilot project’
Pan Pantziarka, Patricia Vandamme, Alicia Soler et al.
Jul 01, 2026 10.1038/s41573-026-01473-9